StemCell Therapy

The stock of Seneca Biopharma, Inc. (NASDAQ:SNCA) hit a new 52-week low and has $0.79 target or 4.00 % below todays $0.83 share price. The 7 months bearish chart indicates high risk for the $3.19 million company. The 1-year low was reported on Nov, 18 by Barchart.com. If the $0.79 price target is reached, the company will be worth $127,600 less.The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 10.91% or $0.101 during the last trading session, reaching $0.825. About 143,863 shares traded. Seneca Biopharma, Inc. (NASDAQ:SNCA) has 0.00% since November 18, 2018 and is . It has by 0.00% the S&P500.

More notable recent Seneca Biopharma, Inc. (NASDAQ:SNCA) news were published by: Seekingalpha.com which released: 32 Stem Cell Companies to Watch Seeking Alpha on February 04, 2009, also Seekingalpha.com with their article: An Early Valuation Of Neuralstems NSI-189 For MDD Seeking Alpha published on June 25, 2014, Seekingalpha.com published: 15 Biotech Names For 2015 Seeking Alpha on January 05, 2015. More interesting news about Seneca Biopharma, Inc. (NASDAQ:SNCA) were released by: Finance.Yahoo.com and their article: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimeras Reverse Split, 2 Biotechs To Debut Yahoo Finance published on November 08, 2019 as well as Seekingalpha.coms news article titled: Is It Time To Invest In Stem Cell Biotechs? Seeking Alpha with publication date: June 03, 2016.

Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company has market cap of $3.19 million. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It currently has negative earnings. The Companys lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the original post here:
After Touching 52-Week Low, Is Seneca Biopharma, Inc. (SNCA)'s Near-Term Analysis Negative? - FinanceRecorder

This entry was posted on November 18, 2019 at 7:42 pm and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |